COMMON STOCK PURCHASE WARRANT SEELOS THERAPEUTICS, INC.Seelos Therapeutics, Inc. • September 9th, 2020 • Pharmaceutical preparations
THIS COMMON STOCK PURCHASE WARRANT (the "Warrant") certifies that, for value received, _____________ or its assigns (the "Holder") is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after March 9, 2021 (the "Initial Exercise Date") and on or prior to 5:00 p.m. (New York City time) on March 9, 2026 (the "Termination Date") but not thereafter, to subscribe for and purchase from Seelos Therapeutics, Inc., a Nevada corporation (the "Company"), up to ______ shares (as subject to adjustment hereunder, the "Warrant Shares") of Common Stock. The purchase price of one share of Common Stock under this Warrant shall be equal to the Exercise Price, as defined in Section 2(b).
PLACEMENT AGENCY AGREEMENTPlacement Agency Agreement • September 9th, 2020 • Seelos Therapeutics, Inc. • Pharmaceutical preparations • New York
Introduction. Subject to the terms and conditions herein (this "Agreement"), Seelos Therapeutics, Inc., a Nevada corporation (the "Company"), hereby agrees to sell up to an aggregate of $7,003,350.00 of securities of the Company, including, but not limited to, 8,865,000 registered shares (the "Shares") of the Company's common stock, $0.001 par value per share (the "Common Stock"), and unregistered Common Stock purchase warrants to purchase up to an aggregate of 6,648,750 shares of Common Stock (the "Warrants" and the shares of Common Stock issuable upon exercise of the Warrants, the "Warrant Shares") (the Shares, Warrants and Warrant Shares, collectively, the "Securities") directly to various investors (each, an "Investor" and, collectively, the "Investors") through Roth Capital Partners, LLC (the "Placement Agent") as placement agent. The documents executed and delivered by the Company and the Investors in connection with the Offering (as defined below), including, without limitation,
SECURITIES PURCHASE AGREEMENTSecurities Purchase Agreement • September 9th, 2020 • Seelos Therapeutics, Inc. • Pharmaceutical preparations • New York
This Securities Purchase Agreement (this "Agreement") is dated as of September 4, 2020, between Seelos Therapeutics, Inc., a Nevada corporation (the "Company"), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a "Purchaser" and collectively the "Purchasers").
